Icagen and Pfizer to Research Sodium Ion Channels

Research Triangle Park, NC (Aug. 14)-Icagen signed a worldwide collaboration and licensing agreement with Pfizer (New York) for the discovery, development, and commercialization of compounds that modulate three specific sodium ion channels and could provide treatments for pain and related disorders. Icagen and Pfizer will pool resources to identify compounds that target these three ion channels in a global research and development collaboration supervised by a joint research committee. Pfizer will fund all aspects of the project, including the research and preclinical development work at Icagen, and will gain exclusive worldwide rights to commercialize resulting products. Pfizer also will make an equity investment in Icagen.

The ion channel targets of the collaboration help generate electrical signals in nerve fibers that mediate the initiation, transmission, and sensation of pain. Icagen identified compounds that have demonstrated efficacy in pain models during preclinical studies. Icagen also accumulated intellectual property in this area that includes several promising compounds that target sodium channels.

P. Kay Wagoner, president and CEO of Icagen, said, “Given that there are three different ion channel targets in the collaboration, we believe that there is a possibility for at least three unique products to emerge from this joint effort.”